Biocept Ceo

Nall, President. “Mike is particularly known within our industry for his outstanding leadership capability and commercial vision. Biocept (BIOC +4. Biocept, Inc. 6, 2020 /PRNewswire/ -- Biocept, Inc. Dugan has more than 25 years of industry experience, most recently as president and CEO of professional advisory group practice MCDXI Medical Diagnostics International. Biocept shares were jumping 63. The Board of Directors of Biocept Inc. 13 mins Biocept Announces One-for-Ten Reverse Stock Split Business Insider 22 mins Stocks Fall in Another Volatile Session – Morningstar. Biocept executives and stock owners. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Comparte tu opinión y gana perspectiva de otros corredores de bolsa e inversionistas. Biocept will begin accepting physician-ordered testing to support our clients and public health efforts by expanding our offerings to include COVID-19 testing,” said Biocept CEO Mike Nall. "Working with Biocept better enables the potential rapid development of this new PCR-based COVID-19 assay," said Stella M. 14, 2020 -- (Healthcare Sales & Marketing Network) -- Biocept, Inc. "But after six or seven years with no commercial success," Reiss brought in a new CEO who refocused the company on microfluidics, according to Coutts. 's NASDAQ:BIOC CEO Pay Matters To You. The graphic below shows how CEO compensation at Biocept has changed from year to year. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Biocept Awarded Patent in China for its Circulating Tumor Cell Platform Expanding Intellectual Property Estate to 33 Issued Patents Globally PRNewswire May 28, 2019. BIOCEPT INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. The following slide deck was published by Biocept, Inc. 435 until finishing in the latest session at $0. Biocept to begin coronavirus testing in its highly advanced and certified lab in San Diego. SAN DIEGO, Aug. The declines come after the company issued its financial results, leaving investors with mixed feelings. 62% soared 86% on very heavy volume Monday, after the provider of liquid biopsy tests announced the commercial launch of Target Selector NGS Lung Panel, the liquid biopsy panel developed for lung cancer. Prior to Biocept, he served as Executive Vice President of Sequenom, Inc. Deprecated: implode(): Passing glue string after array is deprecated. These materials are referred to as “cell-free” DNA (cfDNA), and circulating tumor cells (CTCs). Mike Nall has been the CEO of Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. a boutique construction firm. Biocept Inc. Apart from the obvious need to contain the virus’ spread, comes the need for as much testing as possible. The San Diego-based company said it has deepened its affiliation with MultiPlan Inc - a healthcare cost management company - to include the testing services at a pre-negotiated price per test. Biocept to Present at the LD Micro 500 Virtual Conference PR Newswire SAN DIEGO, Aug. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE on 5/5/20. "The healthcare community understands the importance of tracking and monitoring biomarker status in order to successfully treat cancer patients," said Mike Nall, CEO of Biocept. BIOCEPT INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility. He co-founded Forward Ventures and has served as its Managing Partner since 2000. "This patent expands Biocept's international footprint for capturing and analyzing rare cells of interest, including CTCs, and is a further aid. "This agreement affords us added balance sheet strength and flexibility as we further expand our menu of commercial assays and continue to drive physician adoption," said Michael W. ’s ISS governance QualityScore as of N/A is N/A. (NASDAQ: BIOC) via Skype. Biocept Inc (NASDAQ:BIOC) released second quarter results after the bell Wednesday that showed a narrowing loss and increase in commercial test volumes, despite the impact of the coronavirus. 9 million shares at $10. California is among the worst hit; Last week a new single-day death record was set, and the state’s reopening has been rolled back. com you will find a comprehensive list of Penny Stocks & discover the best Penny Stocks to buy, top penny stock news and micro-cap stock articles. BIOC sais that it has partnered with a national clinician network to accept patient samples. Razer CEO on how the gamer giant plans to spend its $500m cash amid record results Razer CEO Min-Liang Tan speaks exclusively to Yahoo Finance UK Biocept, Inc. 5%) is up, albeit on below-average volume, in reaction to its announcement that it has processed more than 20K COVID-19 specimens in its molecular lab, most reported within 48. Revenue fell 23. Biocept - Proactive's One2One Virtual Investor Forum. Dugan brings to Biocept more than 25 years of industry experience, most recently as President and CEO of MCDXI Medical Diagnostics International, a professional advisory group practice where. Biocept has appointed Michael Dugan as its chief medical officer and medical director, responsible for medical policy decision-making and operations of Biocept's CLIA-certified laboratory. Athersys was moving up 8. Biocept, Inc. 27, 2020 /PRNewswire/ -- Biocept, Inc. Nall as President and Chief Executive Officer. Biocept Inc is an early commercial-stage molecular oncology diagnostics company. Share this article. Mike Nall became the CEO of Biocept, Inc. Companies People Investors Funding Rounds Acquisitions Schools Events Hubs Saved. com) is the top online destination for all things Micro-Cap Stocks. To accommodate the robust demand for this testing, we have increased staffing. Below is a representative list of partnering companies for the 2020 CEO & Investor Conference: 20/20 GeneSystems 3E Bioventures 3i Fund A C Binder Corp A2A Pharmaceuticals Ab Studio AbbVie Abingworth Management Accelmed Partners Aceras Partners …. Razer CEO on how the gamer giant plans to spend its $500m cash amid record results Razer CEO Min-Liang Tan speaks exclusively to Yahoo Finance UK Biocept, Inc. Posted on May 1, 2020 By web_exec-20200708-05. Biocept thermo fisher covid. "This agreement effectively expands our managed care network of covered lives at a time when the healthcare community increasingly recognizes the importance of our liquid biopsy tests in helping physicians to determine the optimal treatment for their patients with cancer," said Michael Nall, Biocept's President and CEO. Real time Biocept (BIOC) stock price quote, stock graph, news & analysis.  “Mike is particularly known within our industry for his outstanding leadership capability and commercial vision. Nall, President. Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year. The graphic below shows how CEO compensation at Biocept has changed from year to year. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. 27, 2020 SAN DIEGO, Aug. A free inside look at Biocept offices and culture posted anonymously by employees. com) is the top online destination for all things Micro-Cap Stocks. , an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. CEO Michael Nall says, "We believe COVID-19 testing will be an important part of our business for the immediate future. BioCryst shares were gaining 21. by: to support our clients and public health efforts by expanding our offerings to include COVID-19 testing," said Biocept CEO Mike Nall. 16M Navy contract - Bell Textron was awarded a $272. 5810 Nancy Ridge Dr. The MarketWatch News Department was not involved in the creation of this content. It is worth noting that the CEO compensation consists almost entirely of the salary, worth US$426k. Senior Vice President Corporate Development at Biocept, Inc. "This project further expands on Biocept's initiatives in the COVID-19 PCR testing market and highlights our capabilities to develop high-complexity molecular-based assays based on our core. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces the presentation of data affirming the ability of its Target Selector™ platform to identify potentially actionable mutations in the. Michael Nall - President & CEO. "We look forward to this next. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Source: MarketScreener Biocept: Biocept to Release First Quarter 2020 Financial Results and Host Investor Conference Call on May 13, 2020 (marketscreener. Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. "Expanding patent protection for our Target Selector™ liquid biopsy platform is among our strategic priorities as we seek to grow our global business," said Michael Nall, Biocept's President and CEO. If you have patients who need laboratory testing by Biocept and who may not be able to come to your office for a blood draw, please contact our customer. Biocept Inc (NASDAQ: BIOC) CEO Mike Nall tells Proactive the molecular diagnostics company, is expanding uses for its flagship liquid biopsy Target Selector technology which detects cancer biomarkers. Like Biotheranostics, Biocept also works within the Biotechnology industry. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Michael Nall, Biocept's President and CEO. Biocept wiki. Pacific time). Biocept to Present at the LD Micro 500 Virtual Conference PR Newswire SAN DIEGO, Aug. Biocept nabs new U. 28, 2020, reporting to CEO Francis deSouza. Biocept's blood- based tests are also used by physicians to monitor patients' treatment in a non-invasive manner. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients. Eastern time (10 a. 4, 2020 /PRNewswire/ -- Biocept, Inc. Biocept CEO and President Michael Nall says the company’s Target SelectorTM assays utilize a blood sample to provide biomarker analysis to physicians when tissue biopsies are inadequate or the risk to the patient is too high to attempt a surgical procedure. (BIOC) stock news and headlines to help you in your trading and investment decisions. The graphic below shows how CEO compensation at Biocept has changed from year to year. 6, 2020 /PRNewswire/ --Biocept, Inc. Biocept President and CEO Michael Hall said in a statement that McNeal's experience will be essential as the company works to expand coverage for its OncoCEE-BR breast cancer liquid biopsy test,. As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and therapies. Dear CEO of BIOC. Like Biotheranostics, Biocept also works within the Biotechnology industry. s (NASDAQ:BIOC) CEO Salary Level? Simply Wall St. 435 until finishing in the latest session at $0. Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and. He co-founded Forward Ventures and has served as its Managing Partner since 2000. The Board of Directors of Biocept Inc. has inked a $15 million stock purchase agreement with Chicago-based Aspire Capital Fund LLC. "Working with Biocept better enables the potential rapid development of this new PCR-based COVID-19 assay," said Stella M. Revenue fell 23. We have solved our initial supply chain challenge by obtaining the swabs, reagents and other components of these kits, assembling them, and making them available for physician ordering," said Michael Nall, Biocept's President and CEO. Our mission is to improve outcomes for cancer. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. Implicit in this philosophy is the importance of sound corporate governance. com - 16 - Shares of Biocept Inc. Several other executives at GE are also recently-appointed. "This agreement. (Nasdaq: BIOC), a leading commercial provider. As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and therapies. In the three months ended June 30, revenue was $917,000, compared to $1. Biocept Names New Chief Medical Officer 8:53AM ET 8/24/2020 MT Newswires. 5810 Nancy Ridge Dr. Biocept (BIOC +4. Biocept operates a CLIA-certified, CAP-accredited and BSL-2 safety level lab in San Diego, with licensed and specialized lab staff that have been trained in performing the COVID-19 testing. (BIOC) CEO Michael Nall on Q1 2020 Results - Earnings Call Transcript. Major indices close lower for the 2nd consecutive day Forexlive 35 mins S&P Snaps 5-Week Win as Tech Bulls Go Awol Investing. Corporate governance Biocept, Inc. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall and CFO & SVP of Operations Tim Kennedy joined Christine Corrado at Proactive's New York studio following their attendance at the H. Michael Nall, President and CEO of Biocept, commented, "We believe the findings from this study are valuable as they help in our understanding of ovarian cancer metastasis, and how to improve. "We are very pleased to become a provider for this well-respected IPA, which offers comprehensive and cutting-edge medical care to its member physicians and their patients," said Michael Nall, Biocept's President and CEO. 2 million funding which positions the company […]. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at the Proactive One2One Virtual Investor Forum, North America on Tuesday, August 25 at 1:00 p. Our mission is to improve outcomes for cancer. patent to detect rare mutations and cancer biomarkers 18 Aug 2020 - Seeking Alpha - Article Biocept to provide COVID-19 testing to multi-state locations 13 Aug 2020 - Seeking. , a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. com you will find a comprehensive list of Penny Stocks & discover the best Penny Stocks to buy, top penny stock news and micro-cap stock articles. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Michael Nall, Biocept's President and CEO. SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. Biocept has 32 fewer employees vs. 16M fixed-price-incentive-firm-target contract for the production and delivery of eight UH-1Y and four AH-1Z helicopters for the government of the Czech Republic. Biocept, a molecular diagnostics company focused on liquid biopsies for cancer, recently announced an expansion of its product portfolio with the launch of a blood test for PD-L1 protein expression - a crucial tool for determining immuno-oncology treatment. (NASDAQ:BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically. "We look forward to this next. if Biocept has not regained compliance with the closing bid price requirement by. Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020. (BIOC) CEO Michael Nall on Q4 2019 Results - Earnings Call Transcript. We have solved our initial supply chain challenge by obtaining the swabs, reagents and other components of these kits, assembling them, and making them available for physician ordering," said Michael Nall, Biocept's President and CEO. In the three months ended June 30, revenue was $917,000, compared to $1. Dr Dugan brings to Biocept more than 25 years of industry experience, most recently as president and CEO of MCDXI Medical Diagnostics International, a professional advisory group practice where he consulted with biotechnology companies in oncology diagnostics, medical device development, and clinically related software applications. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. At the time of writing, our data says that Biocept, Inc. 05-20 prnewswire. Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces the appointment of Michael C. Biocept up 5% as COVID-19 test volume ramps Aug 31 / Seeking Alpha - Paid Partner Content Biocept, Inc. 3% to 58 cents at the time of publication Monday. Real time Biocept (BIOC) stock price quote, stock graph, news & analysis. 16M fixed-price-incentive-firm-target contract for the production and delivery of eight UH-1Y and four AH-1Z helicopters for the government of the Czech Republic. (BIOC) stock quote, history, news and other vital information to help you with your stock trading and investing. “We now have eight. Biocept (BIOC) Presents At BIO CEO & Investor Conference 2020 - Slideshow. She has been the Executive Vice President/Chief Operating Officer of the Salk Institute for Biological Studies since 2007 where she manages approximately 1,000 scientific and administrative personnel, and oversees all institutional fiscal, administrative and fund-raising activities. 5 million, or $0. "We are grateful to call San Diego our home and to find a well-suited location that is convenient for our employees," said Michael Nall, President and CEO of Biocept. “Mike is particularly known within our industry for his outstanding leadership capability and commercial vision. Biocept has 32 fewer employees vs. | Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated DNA , both in Circulating Tumor Cells (CTCs) and in plasma (cell free circulating tumor DNA). “The healthcare community recognizes the importance of determining molecular biomarker status in making treatment decisions for cancer patients,” said Michael Nall, President and CEO of Biocept. , a Delaware corporation (the “Corporation”). Biocept President and CEO Michael Hall said in a statement that McNeal's experience will be essential as the company works to expand coverage for its OncoCEE-BR breast cancer liquid biopsy test,. SAN DIEGO, Aug. The group is a commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. Our Research. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE Mark geographies. 27, 2020 SAN DIEGO, Aug. | Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated DNA , both in Circulating Tumor Cells (CTCs) and in plasma (cell free circulating tumor DNA). The best long-term & short-term Biocept, Inc. Senior Vice President Corporate Development at Biocept, Inc. Dugan brings to Biocept more than 25 years of industry experience, most recently as President and CEO of MCDXI Medical Diagnostics International, a professional advisory group practice where he consulted with biotechnology companies in oncology diagnostics, medical device development, and clinically related software applications. 38 per share in the second quarter of 2019. Nall will present a corporate overview at the 22 nd Annual BIO CEO & Investor Conference on Monday. 5%) is up, albeit on below-average volume, in reaction to its announcement that it has processed more than 20K COVID-19 specimens in its molecular lab, most reported within 48. Below is a representative list of partnering companies for the 2020 CEO & Investor Conference: 20/20 GeneSystems 3E Bioventures 3i Fund A C Binder Corp A2A Pharmaceuticals Ab Studio AbbVie Abingworth Management Accelmed Partners Aceras Partners …. was founded in 1997 and is headquartered in San Diego, California. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. Biocept Inc was founded back in 1997 and headquartered in San Diego, California. Biocept, Inc. 27, 2020 /PRNewswire via COMTEX/ -- SAN DIEGO, Aug. Reeves brings more than 25 years of marketing and management experience and comes to Illumina from Cardinal Health, where she was senior VP of enterprise marketing and general manager of the medical. Biocept thermo fisher covid. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. 17:45 EDT Textron subsidiary awarded $272. The P/E ratio of Biocept is -0. PD-L1 is a molecule often expressed on. All-In-One Screener Dividend Income Portfolio Ben Graham Lost Formula Canadian Faster Growers CEO Buys CEO This is the historical insider ownership of Biocept Inc. Like Biotheranostics, Biocept also works within the Biotechnology industry. was founded in 1997 and is headquartered in San Diego, California. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. CytoDyn Inc (OTCQB:CYDY) said it has requested the regulatory pathway for Fast Track approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its leronlimab treatment to provide it to coronavirus patients. He is the Chairman & CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. , and a member of its board of directors. 64% over the past 2 weeks. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces the presentation of data affirming the ability of its Target Selector™ platform to identify potentially actionable mutations in the. Michael Nall, Biocept's President and CEO, added, "We are very proud to be working with VWR, for the distribution of our proprietary liquid biopsy collection tubes. Biocept, Inc. (NASDAQ:BIOC) in 2013. (BIOC) on CEO. we just heared that bioc has until Dec 7 2020 to satisfy the Nasdaq $1 minimum bid requirement. Rumor Buzz of GE Healthcare buyout of Biocept Inc. Biocept Inc. Biocept, Inc. SAN DIEGO, Aug. Nall does hereby certify that: 1. Liquid biopsy firm Biocept Inc. From 1990 to 2000, he served as founding President and CEO of The Sidney Kimmel Cancer Center and from 1978 to 1990, he was a member of the oncology faculty of the University of California, San Diego. In a statement, Michael Nall, CEO at BIOC, had the following to offer: This project further expands on Biocept’s initiatives in the COVID-19 PCR testing market and highlights our capabilities to develop high-complexity molecular-based assays based on our core Switch-Blocker technology for multiple applications, including potentially COVID-19. The Zacks rating relies solely on a company's changing earnings picture. Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020 May 20 2020 - 08:05AM PR Newswire (US) Print SAN DIEGO, May 20, 2020 /PRNewswire/ -- Biocept, Inc. Biocept stock (BIOC) was skyrocketing on Friday as the company announced a liquid biopsy testing partnership with Alliance Global FZ. About Biocept, Inc. 2019-10-14 10:05:49 | Why Biocept, Inc. If you have patients who need laboratory testing by Biocept and who may not be able to come to your office for a blood draw, please contact our customer. Nall, Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility - Clearing the Air" ho. SAN DIEGO, Aug. SAN DIEGO, Feb. 99M with the total Outstanding Shares of 16. Biocept Inc (NASDAQ:BIOC) released second quarter results after the bell Wednesday that showed a narrowing loss and increase in commercial test volumes, despite the impact of the coronavirus. Biocept CEO and President Michael Nall says the company’s Target SelectorTM assays utilize a blood sample to provide biomarker analysis to physicians when tissue biopsies are inadequate or the risk to the patient is too high to attempt a surgical procedure. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at the Proactive One2One Virtual Investor Forum, North America on Tuesday, August 25 at 1:00 p. Nall does hereby certify that: 1. The San Diego-based company said it has deepened its affiliation with MultiPlan Inc - a healthcare cost management company - to include the testing services at a pre-negotiated price per test. (BIOC) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their compensation. (BIOC) más reciente en el foro de Yahoo Finanzas. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall presents to investors at Proactive's One2One Virtual Investor Forum. (BIOC) CEO Michael Nall on Q1 2020 Results - Earnings Call Transcript: May 13: Biocept misses on revenue: May 13: Biocept Reports First Quarter 2020 Financial Results: May 13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter. 16M fixed-price-incentive-firm-target contract for the production and delivery of eight UH-1Y and four AH-1Z helicopters for the government of the Czech Republic. Dugan has more than 25 years of industry experience, most recently as president and CEO of professional advisory group practice MCDXI Medical Diagnostics. The following companies provided updates Monday on their coronavirus programs. Razer CEO on how the gamer giant plans to spend its $500m cash amid record results Razer CEO Min-Liang Tan speaks exclusively to Yahoo Finance UK Biocept, Inc. Biocept, Inc. Biocept is one of Biotheranostics's top rivals. Mike Nall has been the CEO of Biocept, Inc. 4, 2020 /PRNewswire/ -- Biocept, Inc. The biotechnology company said it has provided the regulator with a top-line report from its recently. 8225 Email: [email protected] Biocept (BIOC) reported a 2nd Quarter June 2020 loss of $0. 27, 2020 /PRNewswire/ -- Biocept, Inc. | 3,592 followers on LinkedIn | When treating cancer, it's no longer an either/or world. The analyst consensus points to a rating of ‘Buy’. CytoDyn Inc (OTCQB:CYDY) said it has requested the regulatory pathway for Fast Track approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its leronlimab treatment to provide it to coronavirus patients. 5810 Nancy Ridge Dr. Biocept CEO Michael Nall Now the company has its eye on expansion, planning to roll out similar tests for colorectal cancer and melanomas in the year to come, CEO Michael Nall told FierceDiagnostics. The group is a commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. 27, 2020 SAN DIEGO, Aug. Biocept understands that many of our clients have taken precautionary measures to help prevent the spread of the virus and some maybe delaying or rescheduling patient appointments. Biocept, Inc. Biocept, Inc. Biocept to Present at the LD Micro 500 Virtual Conference PR Newswire SAN DIEGO, Aug. Corporate Governance Biocept, Inc. Pacific time). (CSE:VS) (OTCQB:VRSSF) (FSE:BMVA), at the request of Investment Industry Regulatory Organization of Canada (IIROC), said Friday that it wished to confirm that the company's management is unaware of any material change in the company's operations that would account for the recent increase in market activity, other than the. was founded in 1997 and is headquartered in San Diego, California. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall and CFO & SVP of Operations Tim Kennedy joined Christine Corr See more ». (BIOC) website. Large independent physician association serving California now offers access to Biocept's Target Selector™ liquid biopsy testing for the management of patients diagnosed with cancer SAN DIEGO, Feb. 14, 2020 -- (Healthcare Sales & Marketing Network) -- Biocept, Inc. Biocept has appointed Michael Dugan as chief medical officer and medical director, responsible for medical policy decision-making and operations of Biocept's CLIA-certified laboratory. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. 27, 2020 /PRNewswire/ -- Biocept, Inc. Biocept, Inc. 7729 Company Operator: 858. Biocept CEO Michael Nall Now the company has its eye on expansion, planning to roll out similar tests for colorectal cancer and melanomas in the year to come, CEO Michael Nall told FierceDiagnostics. The MarketWatch News Department was not involved in the creation of this content. Several other executives at GE are also recently-appointed. SAN DIEGO, June 25, 2018 /PRNewswire/ -- Biocept, Inc. "Working with Biocept better enables the potential rapid development of this new PCR-based COVID-19 assay," said Stella M. 2019-05-20 marketwatch. SAN DIEGO, Aug.  “Mike is particularly known within our industry for his outstanding leadership capability and commercial vision. com you will find a comprehensive list of Penny Stocks & discover the best Penny Stocks to buy, top penny stock news and micro-cap stock articles. Culp is the 12th CEO in the company's history. Nall, Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility - Clearing the Air" ho. 27, 2020 SAN DIEGO, Aug. BIOC 25/07/2020 05:38:05 1-888-992-3836 Free Membership Login Monitor. 3 months Biocept, Inc. com) SAN DIEGO, April 29, 2020 /PRNewswire/ -- Biocept, Inc. Senior Vice President Corporate Development at Biocept, Inc. SAN DIEGO, Feb. Biocept Inc is an early commercial-stage molecular oncology diagnostics company. Togo Group CEO on road trip trends. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and. NASDAQ Updated Sep 4, 2020 11:59 PM. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, and Aegea Biotechnologies, Inc. The conference call can be accessed by dialing (855) 656-0927 for domestic callers. Mike Nall has been the CEO of Biocept, Inc. 2019-10-14 10:05:49 | Why Biocept, Inc. Biocept wiki. 7729 Company Operator: 858. Biocept, Inc. /PRNewswire/ -- Biocept, Inc. 78%, while year-to-date (YTD) performance is 85. Nall will present a corporate overview at the 22 nd Annual BIO CEO & Investor Conference on Monday. 435 until finishing in the latest session at $0. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Biocept CEO Michael Nall in a statement. NEW YORK -- Biocept - Get Report shares are rallying 6. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. 13, 2020 /PRNewswire via COMTEX/ -- SAN DIEGO, Aug. in conjunction with this event. 27, 2020 /PRNewswire via COMTEX/ -- SAN DIEGO, Aug. Encuentra el debate de accionesBiocept, Inc. Biocept, Inc. "We have assembled over 80,000 specimen collection kits to date and have reordered components for an additional 80,000. Biocept will hold a conference call today at 4:30 p. Mike Nall became the CEO of Biocept, Inc. 27, 2020 /PRNewswire/ -- Biocept, Inc. , belongs to Healthcare sector and Diagnostics & Research industry. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. (NASDAQ:BIOC) in 2013. (NASDAQ:BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable. (BIOC) más reciente en el foro de Yahoo Finanzas. Biocept's Chairman of the Board is David F. Biotheranostics. "This agreement provides Biocept with new incremental revenue for R&D development services and, if successfully developed. Eastern time to discuss these results and answer questions. This analysis aims first to contrast CEO compensation. CEO Rating. Nall is a healthcare executive with over 25 years of experience. The best long-term & short-term Biocept, Inc. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Real-time discussion about Biocept, Inc. In this SNNLive Video Interview, our host spoke with Mike Nall, CEO of Biocept, Inc. Our Research. Biocept is a Public company that was founded in San Diego, California in 1997. Tim Kennedy - SVP, Operations. com Morningstar 24 mins Wild up and down day for US equities. , a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at the LD Micro 500 Virtual Conference on Wednesday, September 2, at 10:40 a. 's NASDAQ:BIOC CEO Pay Matters To You. , Suite 150 San Diego, CA 92121 Customer Service: 888. Biocept, Inc. filed as a Statement & Designation By Foreign Corporation in the State of California on Thursday, August 1, 2013 and is approximately seven years old, as recorded in documents filed with California Secretary of State. NEW YORK (GenomeWeb) – Communicating with shareholders in a letter earlier this month, Biocept CEO Michael Nall said that the company expects to launch a pilot program this year that allows select customers to move one aspect of the firm's liquid biopsy test interpretation into their own labs. BioCryst shares were gaining 21. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Biocept's Target Selector™ offering includes the choice of individual biomarker tests or a larger liquid biopsy panel, enabling physicians to select the best approach for each patient. 27, 2020 /PRNewswire/ -- Biocept, Inc. 10, 2020 /PRNewswire/ -- Biocept, Inc. , a biotechnology company focused on the development of novel biological products for the treatment of. (BIOC) stock quote, history, news and other vital information to help you with your stock trading and investing. Large independent physician association serving California now offers access to Biocept's Target Selector™ liquid biopsy testing for the management of patients diagnosed with cancer SAN DIEGO, Feb. Togo Group CEO on road trip trends. Biocept - Proactive's One2One Virtual Investor Forum. As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and therapies. 10, 2020 /PRNewswire/ -- Biocept, Inc. We partner with industry leaders and major cancer centers, continually advancing the field of. BIOCEPT INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated DNA , both in Circulating Tumor Cells (CTCs) and in plasma (cell free circulating tumor DNA). Eastern time to discuss these results and answer questions. The group is a commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. SAN DIEGO, Aug. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. | 3,574 Follower auf LinkedIn | When treating cancer, it's no longer an either/or world. Michael Nall, Biocept's President and CEO, added, "We continue to lead the way in innovation for liquid biopsy technology, and this latest patent demonstrates our leadership in creating new methodologies to identify potential cancer cells, or cells of any type for that matter. Then we'll look. This is hosted by Maxim Group and M-Vest being held on Wednesday, May 27. (NASDAQ:BIOC) in 2013. Biocept, Inc. In a statement, Michael Nall, CEO at BIOC, had the following to offer: This project further expands on Biocept’s initiatives in the COVID-19 PCR testing market and highlights our capabilities to develop high-complexity molecular-based assays based on our core Switch-Blocker technology for multiple applications, including potentially COVID-19. 18) per share. Corporate governance Biocept, Inc. as Chief Medical Officer and Medical Director. Chandler is a member of Biocept's science and technology committee. Biocept has appointed Michael Dugan as chief medical officer and medical director, responsible for medical policy decision-making and operations of Biocept's CLIA-certified laboratory. 5810 Nancy Ridge Dr. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. Nall, Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility - Clearing the Air". In a statement, Michael W. (NASDAQ:BIOC) in 2013. Address: 5810 Nancy Ridge Drive, Suite 150, San Diego, CA, USA, 92121: Telephone: +1 858 320-8200: Website: https://www. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. 2019-05-20 marketwatch. (Nasdaq: BIOC), a Biocept's President and CEO. Biocept (BIOC) Recent Earnings. 16M Navy contract - Bell Textron was awarded a $272. June 19, 2020 – NEXT SUPER STOCK presenter, NexTech AR Solutions (OTC: NEXCF) (CSE: NTAR) Interview with CEO Evan Gappelberg. Corporate Governance Biocept, Inc. Biocept, Inc. Nall is the President and Chief Executive Officer of Biocept, Inc. Biocept operates a CLIA-certified, CAP-accredited and BSL-2 safety level lab in San Diego, with licensed and specialized lab staff that have been trained in performing the COVID-19 testing. It comes after the group's one-for-ten (ten shares combined and converted into one) reverse stock split which became effective at 5pm EST on September 4 this year. All Insiders CEO Buys/Sells Insider Trends Insider Cluster CFO Buys/Sells Guru + Insider Double Buys Triple buys Biocept Inc $ 0. This is hosted by Maxim Group and M-Vest being held on Wednesday, May 27. , Suite 150 San Diego, CA 92121 Customer Service: 888. (NASDAQ:BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable. CEO Rating. (NASDAQ:BIOC) since 2013. The group is a commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. 27, 2020 /PRNewswire/ -- Biocept, Inc. Biocept (BIOC) Presents At BIO CEO & Investor Conference 2020 - Slideshow. com) SAN DIEGO, April 29, 2020 /PRNewswire/ -- Biocept, Inc. 38 per share in the second quarter of 2019. Joining me from Biocept are Michael Nall, President and Chief Executive Officer; Tim Kennedy, Senior Vice President of Operations and Chief Financial Officer; and Cory Dunn, Senior Vice President. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Michael Nall, Biocept's President and CEO. , Chief Business Officer of Aegea. Biocept Names New Chief Medical Officer 8:53AM ET 8/24/2020 MT Newswires. "The healthcare community understands the importance of tracking and monitoring biomarker status in order to successfully treat cancer patients," said Mike Nall, CEO of Biocept. (NASDAQ: Fisher by deriving synergies from the combination of cutting-edge technologies and services from both companies," said Biocept's President and CEO Michael Nall. BioCryst shares were gaining 21. Corporate governance Biocept, Inc. Real-time streaming quotes of the NASDAQ Composite index components. in conjunction with this event. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall presents to investors at Proactive's One2One Virtual Investor Forum. Biocept, Inc. Togo Group CEO on road trip trends. Biocept Inc. Price to Earnings Ratio vs. Shares of the firm increased above 4% after the bell as the Q4 loss came in better-than-expected. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. Biocept will begin accepting physician-ordered testing to support our clients and public health efforts by expanding our offerings to include COVID-19 testing,” said Biocept CEO Mike Nall. com) SAN DIEGO, May 20, 2020 /PRNewswire/ -- Biocept, Inc. "This agreement. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Razer CEO on how the gamer giant plans to spend its $500m cash amid record results Razer CEO Min-Liang Tan speaks exclusively to Yahoo Finance UK Biocept, Inc. Run by investors for investors Proactive Investors is a Leading source of in-depth comment, analysis, financial news, press releases and share price data on small to large capitalised companies on the Australian Stock Exchange, Toronto Stock Exchange. (the "Company") sets high standards for the Company's employees, officers and directors. Brazil Patent Granted for Biocept's Target Selector™ Oncogene Mutation Enrichment and Detection Platform - Biocept, Inc. Biocept, Inc. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Michael Nall, Biocept's President and CEO. Biocept, Inc. I became the interim CEO in November of 2012 and completed the hiring of the full time CEO in March of 2013 at which time I assumed the role of Chairman of. Should You Worry About Biocept, Inc. Biocept - Proactive's One2One Virtual Investor Forum. 's ISS Governance QualityScore as of N/A is N/A. SAN DIEGO, Aug. 14, 2020 -- (Healthcare Sales & Marketing Network) -- Biocept, Inc. Biocept Inc. About Biocept, Inc. Biocept is one of Biotheranostics's top rivals. BIO Investor Forum PRESIDENT AND CEO , BIOCEPT San Diego, CA , California, United States. Entering into the global market with a scaled offering for liquid biopsy is the first step toward growing from an exclusive CLIA lab business to a technology and products company. "Our highly sensitive and highly specific assays that can profile cancer-associated biomarkers from a blood sample demonstrate a clear advancement in the move to precision medicine," said Biocept's president and CEO, Michael Nall, in a statement. See the company profile for Biocept, Inc. 27, 2020 /PRNewswire/ -- Biocept, Inc. 13, 2020 /PRNewswire via COMTEX/ -- SAN DIEGO, Aug. Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020. BIOC Stock Message Board: CEO interview. Athersys was moving up 8. Biocept, Inc. Biocept, Inc. See Michael W Nall's compensation, career history, education, & memberships. (BIOC) como el resumen financiero, información sobre la industria y el sector, la cantidad de empleados, la gestión corporativa, los miembros ejecutivos clave y sus compensaciones. Here’s what’s happening: Stop […]. The best long-term & short-term Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at the Proactive One2One Virtual Investor Forum, North America on Tuesday, August 25 at 1:00 p. Nall as President and Chief Executive Officer. Dear CEO of BIOC. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. "MCCP's network includes 47 million covered lives, with some members covered by multiple plans. BIOCEPT INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. The group is a commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. Versus Systems, Inc. The MarketWatch News Department was not involved in the creation of this content. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. It comes after the group's one-for-ten (ten shares combined and converted into one) reverse stock split which became effective at 5pm EST on September 4 this year. BIOC Stock Message Board: I don't know about the CEO, but constant. Biocept offers liquid biopsies for lung, breast, gastric, colorectal, prostate, and skin cancers. Biocept will begin accepting physician-ordered testing requests for patients to receive the COVID-19 molecular diagnostic test developed by Carlsbad's ThermoFisher starting April 15. Business: Diagnostic Hired: Michael Nall as president and CEO, formerly general manager of North American sales and marketing at General Electric's Clarient Diagnostic Services Inc. Senior Vice President Corporate Development at Biocept, Inc. In the three months ended June 30, revenue was $917,000, compared to $1. Biocept understands that many of our clients have taken precautionary measures to help prevent the spread of the virus and some maybe delaying or rescheduling patient appointments. Nall, Biocept President and CEO, will participate on the. 27, 2020 /PRNewswire/ -- Biocept, Inc. Biocept, Inc. Janko was also the President/CEO of Biocept, Inc. Our Research. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. (BIOC) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their compensation. 7729 Company Operator: 858. Biotheranostics. “Mike is particularly known within our industry for his outstanding leadership capability and commercial vision. Corporate governance Biocept, Inc. com) SAN DIEGO, May 20, 2020 /PRNewswire/ -- Biocept, Inc. "The healthcare community understands the importance of tracking and monitoring biomarker status in order to successfully treat cancer patients," said Mike Nall, CEO of Biocept. (Nasdaq: BIOC), a leading commercial provider. by: to support our clients and public health efforts by expanding our offerings to include COVID-19 testing,” said Biocept CEO Mike Nall. Chandler is a member of Biocept's science and technology committee. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. , an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. 4, 2020 /PRNewswire/ -- Biocept, Inc. "This agreement effectively expands our managed care network of covered lives at a time when the healthcare community increasingly recognizes the importance of our liquid biopsy tests in helping physicians to determine the optimal treatment for their patients with cancer," said Michael Nall, Biocept's President and CEO. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at the LD Micro 500 Virtual Conference on Wednesday, September 2, at 10:40 a. , Chief Business Officer of Aegea. "But after six or seven years with no commercial success," Reiss brought in a new CEO who refocused the company on microfluidics, according to Coutts. Dugan has more than 25 years of industry experience, most recently as president and CEO of professional advisory group practice MCDXI Medical Diagnostics. BIOCEPT INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Togo Group CEO on road trip trends. CA, an investment chat community for Canada's small cap markets. (NASDAQ:BIOC) Q2 2019 Earnings Conference Call. , and more recently Trovagene, Inc. 11, 2020 12:11 PM ET. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and. Large independent physician association serving California now offers access to Biocept's Target Selector™ liquid biopsy testing for the management of patients diagnosed with cancer SAN DIEGO, Feb. , an innovative private life science company with an extensive portfolio of issued patents in next-generation nucleic. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W. Biocept Inc. 14, 2020 -- (Healthcare Sales & Marketing Network) -- Biocept, Inc. Biocept to begin coronavirus testing Local. Biocept Inc (NASDAQ:BIOC) released second quarter results after the bell Wednesday that showed a narrowing loss and increase in commercial test volumes, despite the impact of the coronavirus. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. 's ISS Governance QualityScore as of N/A is N/A. The company has a market cap of $71. The following slide deck was published by Biocept, Inc. Biocept Names New Chief Medical Officer 8:53AM ET 8/24/2020 MT Newswires. Mike Nall has been the CEO of Biocept, Inc. 4, 2020 /PRNewswire/ -- Biocept, Inc. 19 mins Biocept Announces One-for-Ten Reverse Stock Split Business Insider 28 mins Stocks Fall in Another Volatile Session – Morningstar. Biocept's Target Selector EGFR assay kit cleared in Europe; shares up. Our mission is to improve outcomes for cancer. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Michael Nall, Biocept's President and CEO. BIOC Stock Message Board: CEO interview. Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020. 27, 2020 /PRNewswire/ -- Biocept, Inc. 27, 2020 /PRNewswire via COMTEX/ -- SAN DIEGO, Aug. Here’s what’s happening: Stop […]. In fact, the company said that it plans to begin accepting oders from physicians and processing these orders starting on April 15, 2020. 62% soared 86% on very heavy volume Monday, after the provider of liquid biopsy tests announced the commercial launch of Target Selector NGS Lung Panel, the liquid biopsy panel developed for lung cancer. (NASDAQ:BIOC) Q2 2019 Earnings Conference Call August 12, 2019 16:30 ET Company Participants Kevin McCabe - LHA, IR Michael Nall - President & CEO Tim Kennedy - SVP, Operations. Biocept (BIOC) reported a 2nd Quarter June 2020 loss of $0. CEO is Michael W. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. Nonetheless, a second press release announcing new patents seems to be providing some cushion for the fall. SAN DIEGO, Aug. Biocept, Inc. The group is a commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. 435 until finishing in the latest session at $0. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. SAN DIEGO, Feb. Biocept CEO and President Michael Nall says the company’s Target SelectorTM assays utilize a blood sample to provide biomarker analysis to physicians when tissue biopsies are inadequate or the risk to the patient is too high to attempt a surgical procedure. 8200 Fax: 858. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. Implicit in this philosophy is the importance of sound corporate governance. Janko was also the President/CEO of Biocept, Inc. Dugan brings to Biocept more than 25 years of industry experience, most recently as President and CEO of MCDXI Medical Diagnostics International, a professional advisory group practice where he consulted with biotechnology companies in oncology diagnostics, medical device development, and clinically related software applications. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. 27, 2020 SAN DIEGO, Aug. "This agreement affords us added balance sheet strength and flexibility as we further expand our menu of commercial assays and continue to drive physician adoption," said Michael W. Hale was appointed Executive Chairman of Biocept in March 2011. 99M with the total Outstanding Shares of 16. (Nasdaq: BIOC), a leading commercial provider. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W. SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. Nall is the President and Chief Executive Officer of Biocept, Inc. - Personalized Medicine From a Liquid Biopsy. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Michael Nall, Biocept's President and CEO. is a commercial stage oncology diagnostics company. , local time, at the offices of Biocept, Inc. 05 per share compared to the net loss attributable to common shareholders of $7. SAVE SEARCH. 14, 2020 /PRNewswire/ -- Biocept, Inc. Mike Nall became the CEO of Biocept, Inc. "We are grateful to call San Diego our home and to find a well-suited location that is convenient for our employees," said Michael Nall, President and CEO of Biocept. SAN DIEGO, Aug. Tim Kennedy - SVP, Operations. "Biocept has successfully. Our mission is to improve outcomes for cancer. Biocept has 32 fewer employees vs. | 3,801 followers on LinkedIn | When treating cancer, it's no longer an either/or world. Stock Price Forecast, BIOC stock price prediction. The MarketWatch News Department was not involved in the creation of this content. He also brings to Biocept diverse HR experience, including Manager of Organization Learning and Development at Starwood Hotel and Resorts, HR Manager with The Walt Disney Company, Director of Technical Services at Perimeter Church, and CEO of Gamy and Ary, Inc. Biocept with ticker code (BIOC) now have 1 analysts covering the stock. The group operates and supports more than 50 facilities in multiple states, with most located. 2020 is expected to be a huge year for penny stocks. Salaries, reviews and more - all posted by employees working at Biocept. 24, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. The conference call can be accessed by dialing (855) 656-0927 for domestic. A seasoned veteran in the molecular diagnostics and liquid biopsy industries, Mr. 1 per cent yesterday after the US liquid biopsy cancer tests developer announced plans to raise USD 6. The Board of Directors of Biocept Inc. As healthy and diseased tissue interact with the bloodstream, they release both cellular and genetic material into the circulation. 13 mins Biocept Announces One-for-Ten Reverse Stock Split Business Insider 22 mins Stocks Fall in Another Volatile Session – Morningstar. 27% to trade at $2. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's. Below is a representative list of partnering companies for the 2020 CEO & Investor Conference: 20/20 GeneSystems 3E Bioventures 3i Fund A C Binder Corp A2A Pharmaceuticals Ab Studio AbbVie Abingworth Management Accelmed Partners Aceras Partners …. Our liquid biopsies have been used by doctors in thousands of patient cases. 27, 2020 SAN DIEGO, Aug. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. 38 per share in the second quarter of 2019. com - SAN DIEGO, May 20, 2020 /PRNewswire/ - Biocept, Inc. Biocept stock (BIOC) was skyrocketing on Friday as the company announced a liquid biopsy testing partnership with Alliance Global FZ. Dugan brings to Biocept more than 25 years of industry experience, most recently as President and CEO of MCDXI Medical Diagnostics International, a professional advisory group practice where he consulted with biotechnology companies in oncology diagnostics, medical device development, and clinically related software applications. Biocept (BIOC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). Dear CEO of BIOC. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. Michael Nall, Biocept's President and CEO, added, "We continue to lead the way in innovation for liquid biopsy technology, and this latest patent demonstrates our leadership in creating new methodologies to identify potential cancer cells, or cells of any type for that matter.
© 2006-2020